| Dec'17 | Dec'16 | Dec'15 | Dec'14 | |||
|---|---|---|---|---|---|---|
Revenue from collaboration agreement | ||||||
21,300 | 0 | 0 | - | |||
Operating expenses: | ||||||
Research and development with related party | ||||||
- | - | 11,611 | 7,568 | |||
Research and development | ||||||
140,039 | 58,275 | 13,956 | 6,947 | |||
General and administrative | ||||||
33,657 | 14,903 | 10,508 | 6,175 | |||
Total operating expenses | ||||||
173,696 | 73,178 | 36,075 | - | |||
Loss from operations | ||||||
-152,396 | -73,178 | -36,075 | -20,690 | |||
Interest income, net | ||||||
3,520 | 780 | 199 | 18 | |||
Net loss | ||||||
-148,876 | -72,398 | -35,876 | -20,672 | |||
Accretion of redeemable convertible preferred stock | ||||||
- | - | - | 34 | |||
Net loss attributable to common stockholders | ||||||
- | - | - | -20,706 | |||
Per share information: | ||||||
Net loss per share of common stock, basic and diluted (in dollars per share) | ||||||
-5.31 | -3.46 | -2.12 | -3.06 | |||
Weighted average shares outstanding, basic and diluted diluted (in shares) | ||||||
28,035 | 20,905 | 16,894 | 6,773 | |||